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Introduction
The incidence of idiopathic pulmonary fibrosis (IPF) has been steadily increasing in the last two decades [1, 2] . Average survival is only 3e5 years from the time of diagnosis [3, 4] . However, the clinical course of IPF is highly unpredictable, varying from a rapid, relentless progression [5e7], to a slow, steady deterioration, or a stepwise decline, with periods of stability alternating with acute respiratory worsening [8, 9] . This makes it challenging to define prognosis in IPF patients and to determine the right time window for lung transplantation (LTx) referral, listing and priority status on the waitlist. While one may consider LTx referral premature at the early stages of the disease, a precipitous, unexpected clinical deterioration may dramatically worsen the functional status and preclude LTx permanently [10] .
Reliable staging systems for IPF are critically needed. The pathophysiology of IPF is complex, and individual pulmonary function tests (PFTs) may not be the most accurate in representing disease severity and prognosis [11] . Previous studies demonstrated only a moderate correlation between PFTs, exercise capacity, dyspnea and extent of fibrosis on high resolution computed tomography (HRCT) in patients with IPF [12e14] . This suggests that exercise intolerance in these patients is multifactorial, and may not be entirely represented by functional variables alone. The presence of associated pulmonary hypertension or concomitant emphysema can also impact the severity of symptoms and PFTs results [15, 16] .
In 2003, a Composite Physiologic Index (CPI) was developed to predict the total extent of pulmonary fibrosis using several physiology variables, while taking into account the presence of emphysema, and was found to predict mortality better than single functional variables [17] . The concept of combining variables from different domains to better capture the global impact of disease severity was further expanded with the development of the Gender, Age, Physiology (GAP) staging system, which consists of 4 components (gender, age, forced vital capacity (FVC) and diffusing lung capacity for carbon monoxide (DLCO) [18] , and the RIsk Stratification scorE (RISE), which is based on the Medical Research Council Dyspnea Score (MRCDS), 6-min walk distance (6MWD) and CPI [3] . Both GAP [18] and RISE [3] demonstrated to be superior to individual parameters in predicting mortality.
The fact that mortality in the waitlist is highest among patients with IPF dictates that the selection process should be improved. Multi-dimensional scores specifically designed for IPF have not yet been evaluated in patients being assessed for LTx to predict death after LTx assessment and on the waitlist. We hypothesized that in patients with IPF assessed for LTx, multi-dimensional scores predict mortality accurately. The lung allocation score (LAS), a composite score developed for all patients considered for LTx, was also considered.
Material and methods
Six-hundred-twenty-three patients with "pulmonary fibrosis" assessed for LTx at the Toronto Lung Transplant Program and Lung Transplant Satellite Clinic in London, Ontario, between January 2003 and December 2014 were screened for eligibility. Patients with a known cause of interstitial lung disease (ILD) (collagen vascular diseases, drug toxicities, domestic or professional environmental exposures), patients with incomplete data and patients who died of causes unrelated to IPF (n ¼ 18) were excluded. HRCTs were reviewed by a blinded chest radiologist with expertise in ILD (SK).
Three-hundred-two patients with a diagnosis of IPF meeting the ATS criteria [7] and complete data were included. Diagnosis was based on a retrospective, independent review of radiographic and pathologic data. Patients who were subsequently either listed (n ¼ 247) or not listed (n ¼ 55) for LTx were all considered, but a separate analysis was repeated in the first cohort alone. In 56 subjects, the diagnosis of IPF was based on a definite usual interstitial pneumonia (UIP) pattern on surgical lung biopsies, and on a radiographic pattern of definite or possible UIP [7] ; in 246 subjects, diagnosis was based on a radiographic pattern of possible or definite UIP [7] ; in 195 of these subjects, who subsequently received a LTx, explanted lungs showed a definite pattern of UIP, without any other ILD pattern. Forty-eight patients could not perform DLCO due to respiratory limitations at the time of assessment. There were no other missing data.
Variables considered at the time of assessment included age, gender, body mass index (BMI), PFTs and 6MWD. PFTs and 6MWD were performed according to the ATS guidelines [19, 20] . 6MWD values were also expressed as percent of predicted [21] . The severity of chronic dyspnea was rated according to the MRCDS [22] (Supplementary Table 1 ).
Multi-dimensional scores (Table 1) included LAS [23] , CPI [17] , GAP [18] ; and RISE, calculated as previously described [3] . The acronym was changed from "ROSE" to "RISE" in order to avoid confusion with the "Rapid On-Site Evaluation" used for fine needle aspiration cytology. Since the LAS was introduced only in 2005, all LAS were independently recalculated based on chart review.
The study protocol was approved by the University Health Network Research (n.14e8274) and Western University (n.101386) Ethics Boards.
Statistics
Values are expressed as mean ± standard deviation. The endpoint was 12-month mortality before LTx, with LTx handled as a competing risk. Once transplanted, patients were censored and follow-up terminated. The Kolmogorov-Smirnov test was used for distribution analysis.
In order to account for the competing risks of LTx and death in a population of patients undergoing LTx assessment, the Fine-Gray competing risk regression analysis was used to identify significant variables predicting survival status [24] . Results were summarized as subdistribution hazard ratios (SHRs), representing the relative risk of dying prior to lung transplantation.
C-statistics was used to assess the accuracy of outcome prediction. To account for the competing risk of LTx, time-dependent receiver operating characteristics (ROC) and areas under the curve (AUC) to predict 12-month mortality were estimated using the method described by Blanche et al. [25] Optimal cut-offs for different variables to detect mortality were defined using ROC analysis. AUC were compared according to the methods of DeLong et al. [26] Whenever patients were unable to perform a DLCO due to respiratory limitations, this was considered as DLCO (% pred) 36% pred or CPI>52 (cutoffs identified by ROC analysis against mortality), as DLCO is heavily weighted in the CPI calculation [17] . The inability to perform DLCO was given 3 points in the GAP staging [18] . Twelve-month transplant-free survival (time from assessment to death) was evaluated using Kaplan-Meier curves and the log rank test. P values < 0.05 were regarded as significant. GraphPad (MacKiev, San Diego, CA) and Stata (StataCorp, College Station, TX) softwares were used.
Results

Mortality after LTx assessment
Baseline characteristics are summarized in Table 2 . The majority of patients were male (72%), with a severe level of lung function impairment (median FVC 49%, DLCO 38%) and reduced exercise capacity (median 6MWD 330 m, 68%).
Status at the end of the observation period (12 months after LTx assessment) was determined: 134 patients (45%) had received a LTx, 63 patients (21%) had died before LTx and 105 (34%) patients remained alive without LTx. The cumulative incidence of death and LTx in the 12 months following LTx assessement is shown in Fig. 1A . While in the first 3 months the incidence of LTx and death events was similar, the incidence of LTx started to increase at a faster rate at month 4. Deaths grouped according to the GAP (Fig. 1B ) and the RISE (Fig. 1C) stages showed a consistent increase of mortality with higher scores.
Considering only subjects who were actively listed for LTx (n ¼ 247), there were 50 deaths (20.2%) on the waiting list; thirty of these subjects had a RISE of 3 and only one had a RISE of 1; fifteen of them had a GAP stage of 3. The distribution of outcomes for each stage in this cohort in shown in Fig. 2 : deaths were more frequents in patients with higher stages.
The characteristics of survivors and non-survivors at 12 months after assessment were compared (Table 3) . Age, gender and BMI were not significantly different. Lung function measures, except FVC, were significantly worse and MRCDS was significantly higher in non-survivors. All multi-dimensional scores were also significantly higher in non-survivors.
Prediction of mortality after LTx assessment and on the LTx waitlist
Fine-Gray competing risk regression analysis demonstrated that higher multi-dimensional scores were significantly associated with 12-month mortality ( Table 3 and are very similar to those found in the total population, although slightly inferior.
The prediction discrimination of multi-dimensional scores towards 12-month mortality after assessment was further investigated with ROC analysis (c-statistics), still accounting LTx as a competing event (Table 5 , Supplementary Fig. 1 ). Accuracy in predicting mortality was relatively high for LAS (sensitivity 71%, specificity 86%, AUC 0.78), CPI (sensitivity 67%, specificity 82%, AUC 0.75), GAP stage (sensitivity 59%, specificity 74%, AUC 0.67) and RISE (sensitivity 71%, specificity 84%, AUC 0.78). Comparing AUC curves, the difference between RISE and GAP stage was significant (p ¼ 0.0448), favoring the first, while the difference between RISE and GAP index and between CPI and LAS were not significant. There was also no significant difference between RISE and CPI. Results for individual variables (MRCDS, FVC, DLCO, 6MWD m and % pred) are shown in Supplementary Table 4 and are overall inferior to those of multi-dimensional scores. C-statistics results in the cohort including only listed patients are shown in Supplementary Table 5 and are again very similar, although slightly inferior, to those obtained in the cohort including all assessed patients.
Kaplan-Meier survival analysis grouped by multi-dimensional scores showed a significant discriminatory power towards mortality for all staging systems (Fig. 3) . Kaplan-Meier curves for individual scores of GAP stage and RISE are shown in Supplementary  Figs. 2 and 3 , respectively. In regards to the GAP components, survival tended to be worse in females ( Supplementary Fig. 4 ), and was not significantly different among the age groups established in the GAP system ( Supplementary Fig. 5 ).
Discussion
Lung transplantation is the only therapy proven to improve long term survival in patients with IPF [10] , but unfortunately mortality Abbreviations as in Tables 1 and 2. on the waiting list is highest amongst these patients [10, 27] , which implies that improvement in the assessment process is needed. Many patients are referred to LTx late, often after experiencing an unexpected, rapid progression of disease following a period of relative stability. Previous studies found PFTs to be remarkably poor predictors of mortality in patients with IPF assessed for LTx [28, 29] . In this study, we found that IPF-specific multi-dimensional scores improved the discrimination of mortality prediction after LTx assessment as compared to individual variables, with results analogous to the commonly used, although more complex LAS. Mortality among actively listed patients was indeed significant (20%). If validated for this specific purpose, multi-dimensional scores could potentially be used to help guide decisions on the timing of referral and listing for LTx. To our knowledge, this is the first study evaluating the prognostic value of multi-dimensional scores in IPF patients being considered for LTx. Once patients are placed on the waitlist, death and LTx become competing events, as transplant impedes the occurrence of the event of interest (death). A competing risk Abbreviations as in Tables 1 and 2 . Abbreviations as in Tables 1 and 2 . approach was used in both the regression and c-statistics (ROC) analysis. Fine-Gray regression analysis provides non-parametric estimation of the cumulative incidence for an event of interest in the presence of competing risk events [24] . In regard to c-statistics, we adopted the method described by Blanche et al. in estimating AUCs for clinical outcomes with competing risks [25] . Limited data available suggests that waitlist mortality for IPF in the United States has improved, although remains high [27] since the introduction of the LAS in 2005 [23] . LAS is a composite score derived from the estimates of survival probability both on the waitlist and post-transplant for all patients eligible for LTx [23] . LAS is calculated on the basis of numerous clinical information collected for each patient, including PFTs, need for oxygen or ventilatory support, exercise capacity, functional status, and hemodynamic data [23] . Another strength of the LAS is that it was designed considering also post-transplant survival. Chen et al. found that 12-month waitlist mortality for IPF had decreased from 20 to 11% after the introduction of LAS, yet remained higher than the 3% 12-month mortality observed among patients with COPD [27] . Similarly, Nathan et al. found that the probability of death on the list among candidates with IPF was lower (13% for single LTx candidates, 20% for bilateral LTx candidates) after the adoption of the LAS system (2005e07) than that in the pre-LAS (2002e04) period (22 and 30%, respectively) [31] . In contrast, Merlo et al., found that 12-month survival under the LAS system in a general population of LTx candidates was similar to that of historic reports [32] . In our study, LAS indeed demonstrated a good discriminatory power (sensitivity 71%, specificity 86%; cutoff value 41) towards 12-month mortality. It should be noted that a direct comparison between GAP, RISE and LAS, CPI in terms of SHR is not totally impartial, as the first 2 scores have a much different scale (1e3) from LAS and CPI, which are continuous. Nevertheless, CPI demonstrated a comparable discriminatory power to LAS in all analyses, and the comparison of AUC curves did not yield a significant difference. CPI represents a much simpler score to calculate, being based only on lung physiology.
The RISE was previously developed using a cohort of newly diagnosed IPF patients, who were followed prospectively for a 3-year period, after MRCDS, 6MWD and CPI were identified as independent, significant predictors of mortality [3] . Previous studies separately identified these 3 components as significant prognostic factors in IPF [17, 33] . The RISE further expands the prognostic power of CPI by adding routine clinical variables (dyspnea and exercise capacity) into a more comprehensive, yet inexpensive and easy to calculate score. In this study, the individual components of RISE were confirmed to be significantly associated with mortality after a LTx assessment, and RISE was shown to be as accurate as LAS in terms of mortality discrimination. In the cohort of listed patients, half of those who died on the wailist had a RISE of 3, and could potentially have received higher prioritization on the waitlist. AUC for RISE was significantly higher than the one for the GAP stage, but not significantly higher than the GAP index. With a relatively high sensitivity (71%) and higher specificity (84%) in predicting death after LTx assessment and on the wailist, RISE may be useful in identifying patients that should be actively listed for LTx, and could be used to determine the priority status on the waitlist.
The GAP stage has been shown and validated to predict mortality in two large, retrospective cohorts of IPF patients [18] , although it was not associated with differences in longitudinal lung function decline [34] . Multi-dimensional components of GAP include older age, male gender and worse physiology (FVC, DLCO) as risk factors for death [18] . While DLCO, but not FVC, at the time of assessment was confirmed to be a strong predictor of mortality in our study, older age and female, rather than male, gender were weakly associated with poor outcome. The fact that our study included only patients with advanced disease assessed for LTx, as opposed to a general population of subjects with IPF, could account for some of the differences in these findings.
A few other studies have considered prognostic factors in patients with IPF assessed or listed for LTx. Lederer et al. demonstrated that higher 6MWD (>207 m) was strongly and independently associated with waitlist survival, although LTx was not considered as a competing event [35] . In our study, 6MWD (both meters and % pred, which is a component of RISE) strongly predicted death in all analyses. Since both RISE and LAS include FVC and 6MWD in their calculation, a multivariate analysis including the 2 scores was not considered appropriate. With concomitant factors, such as pre-existing emphysema and associated pulmonary hypertension, frequently playing an important role in waitlist survival [36e41], a comprehensive assessment with multidimensional domains that are better able to capture the complex pathophysiology of IPF seems most appropriate. Current guidelines of the International Society for Heart and Lung Transplantation for timing of LTx referral for IPF patients recommend the use of different radiographic, physiologic and exercise parameters, including FVC, DLCO, 6MWD [42] . Functional and exercise variables are captured in multi-dimensional scores, which, in this study, predicted death after LTx assessment with accuracy similar to LAS, despite being much easier to calculate. However, longitudinal studies are needed to investigate whether staging systems specific for IPF could change the way patients are prioritized for LTx.
This study has some limitations. First, a bias may have been introduced by limiting the study only to subjects with a complete dataset, potentially excluding patients with contraindications to LTx, although at the same time this increased the reliability of the analysis. Second, referral patterns to LTx centers may vary widely, which could affect generalizability, until external validation in separate LTx referral centers is provided. Third, this was not a validation study and, as retrospective and exclusively limited to patients assessed for LTx, results may not necessarily be applicable to the general population with IPF. However, time of LTx assessment was consistently considered as the baseline, and the endpoint (death after assessment) was objective in nature, making this cohort highly clinically relevant. Lastly, IPF-specific scores, unlike LAS, were not developed taking into consideration post-transplant survival, and therefore a validation against LAS is needed.
In summary, the variable nature of disease progression in IPF makes prognostication difficult and contributes to high LTx waitlist mortality. Multi-dimensional scores have shown promise as tools to more reliably stage and predict mortality in IPF compared to individual functional measures. We tested these scores in a cohort of IPF patients undergoing assessment for LTx and in listed subjects, and, while not necessarily applicable to the general population of IPF patients, we found that they improved the strength of mortality discriminatory prediction compared to individual functional measures, and were comparable to LAS in terms of accuracy. Validation of these findings should be performed in a prospective cohort of IPF patients undergoing LTx assessment.
Conclusions
While it was reassuring to find that LAS is a good predictor of mortality after LTx assessment, simpler and IPF-specific multidimensional scores such as CPI, GAP and RISE, if validated for the purpose of LTx assessment, could potentially be integrated in the decision-making process of patients being considered for LTx, as tools to optimize the timing of referral and listing. Further studies will be needed to investigate whether IPF-specific scores could improve the listing prioritization process and function as adjuncts to the LAS in determining the need for listing.
